Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

被引：71
作者：
Stahel, R. A. [2 ]
Weder, W. [1 ]
Lievens, Y. [3 ]
Felip, E. [4 ]
机构：
[1] Univ Zurich Hosp, Dept Thorac Surg, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Clin & Policlin Oncol, CH-8091 Zurich, Switzerland
[3] Leuven Univ Hosp, Dept Radiat Oncol, Louvain, Belgium
[4] Vall Hebron Univ Hosp, Med Oncol Serv, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
EXTRAPLEURAL PNEUMONECTOMY; PHASE-II; PEMETREXED PLUS; TRIAL; CISPLATIN; RADIATION; RADIOTHERAPY; COMBINATION; CARBOPLATIN; VALIDATION;
D O I：
10.1093/annonc/mdq173
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：v126 / v128
页数：3
相关论文
共 21 条
[1]   Modified RECIST criteria for assessment of response in malignant pleural mesothelioma [J].
Byrne, MJ ;
Nowak, AK .
ANNALS OF ONCOLOGY, 2004, 15 (02) :257-260
[2]   Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM) [J].
Castagneto, B. ;
Botta, M. ;
Aitini, E. ;
Spigno, F. ;
Degiovanni, D. ;
Alabiso, O. ;
Serra, M. ;
Muzio, A. ;
Carbone, R. ;
Buosi, R. ;
Galbusera, V. ;
Piccolini, E. ;
Giaretto, L. ;
Rebella, L. ;
Mencoboni, M. .
ANNALS OF ONCOLOGY, 2008, 19 (02) :370-373
[3]   Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma [J].
Ceresoli, GL ;
Zucali, PA ;
Favaretto, AG ;
Grossi, F ;
Bidoli, P ;
Del Conte, G ;
Ceribelli, A ;
Bearz, A ;
Morenghi, E ;
Cavina, R ;
Marangolo, M ;
Parra, HJS ;
Santoro, A .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) :1443-1448
[4]   Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma [J].
de Perrot, Marc ;
Feld, Ronald ;
Cho, B. C. John ;
Bezjak, Andrea ;
Anraku, Masaki ;
Burkes, Ronald ;
Roberts, Heidi ;
Tsao, Ming S. ;
Leighl, Natasha ;
Keshavjee, Shaf ;
Johnston, Michael R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1413-1418
[5]   Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems [J].
Edwards, JG ;
Abrams, KR ;
Leverment, JN ;
Spyt, TJ ;
Waller, DA ;
O'Byrne, KJ .
THORAX, 2000, 55 (09) :731-735
[6]   Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials [J].
Fennell, DA ;
Parmar, A ;
Shamash, J ;
Evans, MT ;
Sheaff, MT ;
Sylvester, R ;
Dhaliwal, K ;
Gower, N ;
Steele, J ;
Rudd, R .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) :184-189
[7]   Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma [J].
Jassem, Jacek ;
Ramlau, Rodryg ;
Santoro, Armando ;
Schuette, Wolfgang ;
Chemaissani, Assad ;
Hong, Shengyan ;
Blatter, Johannes ;
Adachi, Susumu ;
Hanauske, Axel ;
Manegold, Christian .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1698-1704
[8]   Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma [J].
Krug, Lee M. ;
Pass, Harvey I. ;
Rusch, Valerie W. ;
Kindler, Hedy L. ;
Sugarbaker, David J. ;
rosenzweig, Kenneth E. ;
Flores, Raja ;
Friedberg, Joseph S. ;
Pisters, Katherine ;
Monberg, Matthew ;
Obasaju, Coleman K. ;
Vogelzang, Nicholas J. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) :3007-3013
[9]   Prophylactic radiotherapy to intervention sites in mesothelioma: A systematic review and survey of UK practice [J].
Lee, Caroline ;
Bayman, Neil ;
Swindell, Ric ;
Faivre-Finn, Corinne .
LUNG CANCER, 2009, 66 (02) :150-156
[10]   RADIOTHERAPY IN MALIGNANT PLEURAL MESOTHELIOMA [J].
McAleer, Mary Frances ;
Tsao, Anne S. ;
Liao, Zhongxing .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (02) :326-337
123